| GRFT + |
CI at varying HIV inhibitiona |
Effectb |
| 50% |
75% |
95% |
| Entry inhibitors |
| 2G12 mAb |
0.97 ± 0.24 |
0.85 ± 0.14 |
0.65 ± 0.02 |
+++ |
| T20 |
1.13 ± 0.11 |
0.96 ± 0.07 |
0.78 ± 0.07 |
++ |
| Reverse transcriptase inhibitors |
| UC-781 |
0.99 ± 0.06 |
0.95 ± 0.02 |
1.06 ± 0.01 |
additivity |
| tenofovir |
0.92 ± 0.11 |
0.58 ± 0.12 |
0.30 ± 0.11 |
+++(+) |
| Integrase inhibitor |
| raltegravir |
1.08 ± 0.14 |
1.02 ± 0.11 |
0.97 ± 0.13 |
additivity |
| Protease inhibitor |
| saquinavir |
0.79 ± 0.23 |
0.67 ± 0.15 |
0.69 ± 0.12 |
+++ |
aMean values ± SEM out of 2-3 experiments are shown, each performed in duplicate
bEffect of drug interaction based at CI95%, whereby CI<0.9 are synergistic; 0.9<CI<1.1 are additive and CI > 1.1 are antagonistic. The degree of synergy: 0.85<CI<0.9: +
(slight synergy); 0.7<CI<0.85: ++ (moderate synergy); 0.3<CI<0.7: +++ (synergy); 0.1<0.3: ++++ (potent synergy) |
